News | Heart Valve Technology | September 11, 2019

Reducing Secondary Mitral Regurgitation in Heart Failure Does Not Improve Two-year Outcomes

MITRA-FR trial results show no reduction in death or hospitalization following MitraClip intervention

Reducing Secondary Mitral Regurgitation in Heart Failure Does Not Improve Two-year Outcomes

September 11, 2019 — Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not lower death and hospitalization at two years compared to standard medical care, according to late breaking results from the MITRA-FR study. Results were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, Aug. 31-Sept. 4 in Paris, France, and published in the European Journal of Heart Failure.[1]

In advanced heart failure the left ventricle dilates, causing the mitral valve to partially close and allow blood to leak back into the left atrium, called mitral regurgitation. It is called “secondary” because the mitral valve is structurally normal but does not work properly due to a dilated left ventricle.

The benefits of percutaneous correction of secondary mitral regurgitation in patients with heart failure is controversial. One-year results of MITRA-FR, first reported at ESC Congress 2018 and published in the New England Journal of Medicine, [2] showed no significant impact of mitral valve repair with the Abbott MitraClip device on death and heart failure hospitalization compared to standard medical treatment. In contrast, the COAPT study found that valve repair significantly reduced heart failure rehospitalization and death after two years of follow-up.[3]

Read the article "MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation."

“Many hypotheses have been suggested to explain the different outcomes between the two randomized trials,” said MITRA-FR principal investigator Prof. Jean-Francois Obadia of Civil Hospices of Lyon, France. “One theory is the longer duration of COAPT. We therefore conducted a two-year follow-up of patients in MITRA-FR.”

Watch the VIDEO: Impact of the COAPT Trial on Heart Failure Patients With Functional Mitral Regurgitation

The new two-year results show that the combined outcome of all-cause death and unplanned hospitalization for heart failure occurred in 63.8 percent of patients who underwent valve repair and 67.1 percent in those who did not, with no significant difference between groups. There were no significant differences between groups when each outcome was analyzed separately. Rates of all-cause mortality were 34.9 percent and 34.2 percent in the intervention and control groups, respectively. Rates of unplanned hospitalization for heart failure were 55.9 percent and 61.8 percent in the intervention and control groups, respectively.

“This analysis confirms the absence of a significant difference in the rate of the composite outcome of death from any cause or unplanned hospitalization for heart failure in symptomatic patients with severe secondary mitral regurgitation treated by percutaneous mitral valve repair plus medical treatment as compared with those receiving medical treatment alone,” said Obadia. “Percutaneous repair remained safe – there was a very small number of prespecified serious adverse events.”

An exploratory analysis of events occurring between 12 and 24 months suggested a lower rate of first hospitalization for heart failure in the intervention group. This was consistent with a divergence in the curves of recurrent hospitalizations for heart failure for each group.

“This repeat event analysis was used as the main endpoint in the COAPT trial and tends to amplify differences compared to the analysis of time to first event, which was the main endpoint in MITRA-FR,” said Obadia. “As for any exploratory analysis of secondary endpoints, the interpretation of such an isolated finding should be viewed cautiously and only considered hypothesis-generating.

Regarding the differing results between the two trials, Obadia said, “In our view, one of the main reasons is patient selection. Differences in inclusion criteria led to more severe mitral regurgitation, less pronounced left ventricular remodelling, lower pulmonary pressure and better right ventricular function in COAPT compared to MITRA-FR. In addition, the run-in period assessed by a central eligibility committee was likely to result in more optimized guideline-directed medical therapy in COAPT than in MITRA-FR. However, this setup may be difficult to implement in everyday practice which rarely achieves optimized therapy.”

Obadia said that medical treatment should remain the first line of treatment for heart failure patients with secondary mitral regurgitation. “MITRA-FR and COAPT provide answers but also more questions,” he said. “The definition of secondary mitral regurgitation has to be revisited taking into account the dynamic function of the heart. More studies are needed to clarify understanding of this complex disease.”

For more information: www.escardio.org

 

References

1. Iung B., Armoiry X., Vahanian A., et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation: Outcomes at 2 years. European Journal of Heart Failure, published online Sept. 2, 2019.  https://doi.org/10.1002/ejhf.1616

2. Obadia J.F., Messika-Zeitoun D., Leurent G., et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018;379:2297–2306. doi: 10.1056/NEJMoa1805374.

3. Stone G.W., Lindenfeld J., Abraham W.T., et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379:2307–2318. doi: 10.1056/NEJMoa1806640.

Related Content

News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
News | Cardiovascular Clinical Studies

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who ...

Home April 07, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

Home April 06, 2022
Home
News | Cardiovascular Clinical Studies

March 25, 2022 – Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the ...

Home March 25, 2022
Home
News | Cardiovascular Clinical Studies

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

Home February 17, 2022
Home
News | Cardiovascular Clinical Studies

February 8, 2022 — A new study is the first to show that a remote cognitive assessment could help with tracking patients ...

Home February 07, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
Subscribe Now